Endothelin Receptor Antagonists in Kidney Disease.

Humans Angiotensin II Type 1 Receptor Blockers / therapeutic use Endothelin A Receptor Antagonists Endothelin Receptor Antagonists Endothelin-1 Endothelins Kidney Kidney Diseases / drug therapy Proteinuria / drug therapy Receptor, Endothelin A
atrasentan endothelin endothelin receptor antagonists (ERAs) kidney disease sparsentan

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Feb 2023
Historique:
received: 30 12 2022
revised: 25 01 2023
accepted: 28 01 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ET

Identifiants

DOI: 10.3390/ijms24043427 PMID: 36834836 PMC: PMC9965540
pubmed: 36834836
pii: ijms24043427
doi: 10.3390/ijms24043427
pmc: PMC9965540
pii:
doi:

Substances chimiques

Angiotensin II Type 1 Receptor Blockers 0
Endothelin A Receptor Antagonists 0
Endothelin Receptor Antagonists 0
Endothelin-1 0
Endothelins 0
Receptor, Endothelin A 0
EDNRA protein, human 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI21/01292
Organisme : Instituto de Salud Carlos III
ID : RD21/0005/0031

Références

Front Endocrinol (Lausanne). 2022 May 19;13:872918
pubmed: 35663316
Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1173-F1179
pubmed: 30864842
Can J Physiol Pharmacol. 2022 Aug 1;100(8):763-771
pubmed: 35531905
Pharmacol Rev. 2016 Apr;68(2):357-418
pubmed: 26956245
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14367-72
pubmed: 9826706
Ther Adv Cardiovasc Dis. 2010 Aug;4(4):231-40
pubmed: 20660536
Am J Physiol. 1990 Aug;259(2 Pt 2):F217-21
pubmed: 2201203
J Med Chem. 2005 Jan 13;48(1):171-9
pubmed: 15634011
Semin Nephrol. 2015 Mar;35(2):125-36
pubmed: 25966344
Eur J Drug Metab Pharmacokinet. 2020 Apr;45(2):227-234
pubmed: 31773427
J Clin Med. 2020 Mar 18;9(3):
pubmed: 32197449
Am J Hypertens. 1998 May;11(5):554-62
pubmed: 9633791
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S232-7
pubmed: 11078385
J Appl Physiol (1985). 1996 Oct;81(4):1510-5
pubmed: 8904561
Braz J Med Biol Res. 2017 Dec 11;51(2):e6373
pubmed: 29267497
J Clin Pharm Ther. 2022 Feb;47(2):146-156
pubmed: 34319626
J Histochem Cytochem. 2006 Nov;54(11):1193-203
pubmed: 16835394
Hypertens Res. 2019 Apr;42(4):469-482
pubmed: 30948820
Diabetologia. 2011 Apr;54(4):979-88
pubmed: 21191784
J Am Soc Nephrol. 2018 Nov;29(11):2745-2754
pubmed: 30361325
Biochem Biophys Res Commun. 1994 Mar 30;199(3):1461-5
pubmed: 8147891
Am J Kidney Dis. 1997 Jan;29(1):2-26
pubmed: 9002526
FEBS Lett. 1996 Mar 25;383(1-2):37-41
pubmed: 8612786
Diabet Med. 2021 Jan;38(1):e14411
pubmed: 33000477
Front Med (Lausanne). 2022 Apr 25;9:848389
pubmed: 35547199
Am J Physiol Renal Physiol. 2003 Oct;285(4):F579-89
pubmed: 12954590
Kidney Int. 2014 Nov;86(5):896-904
pubmed: 24805108
Hypertension. 2010 Nov;56(5):942-9
pubmed: 20823379
Nephrol Dial Transplant. 1992;7(4):288-92
pubmed: 1317517
J Clin Invest. 1997 Mar 15;99(6):1380-9
pubmed: 9077548
Hypertension. 2019 Dec;74(6):1232-1265
pubmed: 31679425
Lancet Diabetes Endocrinol. 2020 Nov;8(11):903-914
pubmed: 33065060
Drugs. 2007;67(5):761-70; discussion 771-2
pubmed: 17385944
Eur J Pharmacol. 2021 Nov 5;910:174445
pubmed: 34492284
J Am Soc Nephrol. 2014 May;25(5):1083-93
pubmed: 24722445
Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):437-49
pubmed: 25604973
Am J Kidney Dis. 2016 May;67(5):728-41
pubmed: 26597926
Cardiovasc Res. 2002 Feb 1;53(2):487-95
pubmed: 11827700
J Clin Med. 2015 May 25;4(6):1171-92
pubmed: 26239552
Arthritis Res Ther. 2022 Jun 1;24(1):130
pubmed: 35650639
Hypertension. 2004 Dec;44(6):974-81
pubmed: 15545511
Am J Kidney Dis. 2021 May;77(5):719-729.e1
pubmed: 33246024
Am J Hypertens. 2001 Jun;14(6 Pt 2):83S-89S
pubmed: 11411770
Handb Exp Pharmacol. 2006;(176 Pt 1):295-329
pubmed: 16999223
Hypertension. 2006 Nov;48(5):965-71
pubmed: 17015777
Physiol Rev. 1993 Apr;73(2):375-411
pubmed: 8475194
J Am Soc Nephrol. 2010 Mar;21(3):527-35
pubmed: 20167702
Kidney Int. 2021 Feb;99(2):346-349
pubmed: 33144213
Am J Physiol Renal Physiol. 2020 May 1;318(5):F1295-F1305
pubmed: 32249614
Am J Physiol Renal Physiol. 2009 Nov;297(5):F1448-56
pubmed: 19675181
Hypertension. 2011 Apr;57(4):772-9
pubmed: 21357275
Front Pediatr. 2019 Jul 23;7:302
pubmed: 31396496
Shock. 2009 Oct;32(4):427-34
pubmed: 19197226
J Cardiovasc Pharmacol. 2002 Jun;39(6):892-900
pubmed: 12021584
Nephrol Dial Transplant. 2011 Mar;26(3):779-89
pubmed: 20813769
Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F977-F985
pubmed: 29846112
Kidney Int. 1996 Feb;49(2):382-7
pubmed: 8821821
Circulation. 2004 Mar 9;109(9):1186-93
pubmed: 14981006
Ther Adv Respir Dis. 2017 Jun;11(6):233-244
pubmed: 28425346
J Pharmacol Exp Ther. 2008 Dec;327(3):736-45
pubmed: 18780830
Am J Physiol. 1985 May;248(5 Pt 1):C550-6
pubmed: 3993773
Nature. 1988 Mar 31;332(6163):411-5
pubmed: 2451132
Drugs. 2014 Jan;74(1):127-33
pubmed: 24297706
Can J Physiol Pharmacol. 2008 Aug;86(8):485-98
pubmed: 18758495
Nat Rev Nephrol. 2012 Feb 21;8(5):293-300
pubmed: 22349487
Life Sci. 2014 Nov 24;118(2):297-305
pubmed: 24373834
Kidney Int. 1996 Sep;50(3):962-72
pubmed: 8872972
Cardiovasc Res. 2020 Aug 1;116(10):1779-1790
pubmed: 31593221
J Am Soc Nephrol. 2009 Mar;20(3):655-64
pubmed: 19144760
Circ Res. 2001 Nov 23;89(11):969-76
pubmed: 11717152
Am J Nephrol. 2016;43(2):74-84
pubmed: 26930122
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2863-7
pubmed: 2649896
Lancet. 2009 Oct 24;374(9699):1423-31
pubmed: 19748665
Kidney Int Rep. 2020 Jan 08;5(4):494-502
pubmed: 32274453
Drug Des Devel Ther. 2019 Mar 22;13:949-964
pubmed: 30962677
Hypertens Res. 1998 Dec;21(4):251-7
pubmed: 9877518
Br J Cancer. 2005 Jun 20;92(12):2148-52
pubmed: 15956965
Kidney Int. 1993 Aug;44(2):440-4
pubmed: 8377387
Br J Clin Pharmacol. 2013 Oct;76(4):573-9
pubmed: 23228194
Lancet. 2019 May 11;393(10184):1937-1947
pubmed: 30995972
Circulation. 2020 Sep 15;142(11):1028-1039
pubmed: 32410463
Am J Physiol. 1995 Sep;269(3 Pt 2):F449-57
pubmed: 7573494
J Am Soc Nephrol. 2011 Apr;22(4):763-72
pubmed: 21372210
Kidney Int. 1992 Jun;41(6):1713-9
pubmed: 1323728
Int J Mol Sci. 2022 Oct 24;23(21):
pubmed: 36361612
Nucleic Acids Res. 2022 Jan 7;50(D1):D1307-D1316
pubmed: 34648031
BMC Nephrol. 2017 Oct 27;18(1):323
pubmed: 29078759
Lancet. 2022 Dec 3;400(10367):1927-1937
pubmed: 36356632
Can J Physiol Pharmacol. 2010 Aug;88(8):840-9
pubmed: 20725142
Circulation. 1991 Oct;84(4):1457-68
pubmed: 1655302
J Med Chem. 1996 May 24;39(11):2123-8
pubmed: 8667356
Br J Pharmacol. 2005 Dec;146(7):1019-26
pubmed: 16231007
J Am Soc Nephrol. 2017 Apr;28(4):1023-1039
pubmed: 28143897

Auteurs

Irene Martínez-Díaz (I)

Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0001-5849-7900

Nerea Martos (N)

Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Carmen Llorens-Cebrià (C)

Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0002-3611-1816

Francisco J Álvarez (FJ)

Travere Therapeutics, Inc., San Diego, CA 92130, USA.

Patricia W Bedard (PW)

Travere Therapeutics, Inc., San Diego, CA 92130, USA.

Ander Vergara (A)

Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0003-1926-0147

Conxita Jacobs-Cachá (C)

Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0003-2518-7847

Maria José Soler (MJ)

Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0003-3621-0766

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antagonistes des récepteurs aux angiotensines › Antagonistes du récepteur de type 1 de l'angiotensine-II › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antagonistes des récepteurs de l'endothéline › Antagonistes du récepteur de type A de l'endothéline › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antagonistes des récepteurs de l'endothéline › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Endothélines › Endothéline-1 › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Endothélines › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations urologiques › Protéinurie › Endothelin Receptor Antagonists in Kidney Disease.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur endothéline › Récepteur de type A de l'endothéline › Endothelin Receptor Antagonists in Kidney Disease.